Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The study is designed to investigate the safety, tolerability and efficacy of DG3173 in
untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and
one dose of octreotide, the current gold standard of medical therapy for acromegaly, with
each patient receiving all doses of DG3173 as well as octreotide.